References

endofocus

FOCUS Эндокринология

FOCUS. Endocrinology

2713-01772713-0185

ООО "Издательство "Перо"

10.15829/2713-0177-2023-3-14

endofocus-45

Research Article

Статьи

Новые перспективы междисциплинарного применения метформина в клинической практике врача: роль в лечении неалкогольной жировой болезни печени

New prospects for the interdisciplinary use of metformin in clinical practice: its role in the treatment of non-alcoholic fatty liver disease

https://orcid.org/0000-0001-6385-540X

Демидова

Т. Ю.

Demidova

T. Yu.

д.м.н., профессор, зав. кафедрой эндокринологии лечебного факультета

ScopusAuthorID: 7003771623

117997, г.Москва, ул. Островитянова, д. 1, Тел.: 8 (916) 670-02-12

Tatyana Yu. Demidova – MD, professor, head of the Department of endocrinology, faculty of general medicine

ScopusAuthorID: 7003771623

109263, Moscow, 4/1 Shkuleva Str.

t.y.demidova@gmail.com

https://orcid.org/0000-0002-1385-0245

Измайлова

М. Я.

Izmailova

M. Ya.

ассистент кафедры эндокринологии лечебного факультета

117997, г. Москва, ул. Островитянова, д. 1

Mariam Ya. Izmailova – assistant of the Department of endocrinology, faculty of general medicine

109263, Moscow, 4/1 Shkuleva Str.

maremizm@gmail.com

https://orcid.org/0000-0002-9603-5886

Белова

М. К.

Belova

K. M.

ординатор 2 года кафедры эндокринологии лечебного факультета

117997, г. Москва, ул. Островитянова, д. 1, Телефон: +79117350363

Karina M. Belova – Resident of the Department of Endocrinology, Faculty of Medicine

109263, Moscow, 4/1 Shkuleva Str., Phone number: +79117350363

belovakarina896@gmail.com

https://orcid.org/0000-0002-8684-6095

Титова

В. В.

Titova

V. V.

ассистент кафедры эндокринологии лечебного факультета

117997, г. Москва, ул. Островитянова, д. 1

Victoria V. Titova – assistant of the Department of endocrinology, faculty of general medicine

109263, Moscow, 4/1 Shkuleva Str.

meteora-vica@mail.ru

ФГАОУ ВО «РНИМУ им. Н. И. Пирогова» Минздрава РоссииPirogov Russian National Research Medical University Moscow

2023

18122023

Гастроэндокринология

4147

2024

Демидова Т.Ю., Измайлова М.Я., Белова М.К., Титова В.В.

Demidova T.Y., Izmailova M.Y., Belova K.M., Titova V.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://endofocus.elpub.ru/jour/article/view/45

На сегодняшний день, несмотря на внедрение методов первичной и вторичной профилактики, хронические неинфекционные заболевания остаются основной причиной высокой заболеваемости и смертности во всем мире. В настоящее время НАЖБП приобретает особое значение в связи с высокой распространенностью, особенно у лиц с метаболическим синдромом и развитием кардиоваскулярных заболеваний и их осложнений. Одним из перспективных направлений лечения НАЖБП является терапия инсулиносенситайзерами, к которым относится метформин. Настоящий обзор посвящен эпидемиологии, патофизиологии НАЖБП и СД 2 типа, а также механизмам действия метформина и его влиянию на некоторые процессы, лежащие в основе развития и взаимосвязи этих заболеваний.

Today, despite the introduction of primary and secondary prevention methods, chronic non-communicable diseases remain the main cause of high morbidity and mortality throughout the world. According to some studies, hepatic component metabolic syndrome and one of the main factors contributing to the development of cardiometabolic diseases is non-alcoholic severe liver disease. According to the results of studies, NAFLD is currently the leading cause of chronic liver diseases worldwide and is closely associated with the development of cardiometabolic pathology, in particular type 2 diabetes and CVD. This review is devoted to the epidemiology, pathophysiology of the close relationship between NAFLD and type 2 diabetes, as well as therapy affecting insulin resistance, a key link connecting these two nosologies.

метформинплейотропные эффектысахарный диабет 2 типаинсулинорезистентностьдислипидемияожирениеметаболический синдромсердечно-сосудистая системанеалкогольная жировая болезнь печени

Metforminpleiotropic effecttype 2 diabetes mellitusinsulin resistancedyslipidemiaobesitymetabolic syndromeinflammationoxidative stresscardiovascular systemmicrovascular complicationsnon-alcoholic fatty liver diseaseintestinal microbiota

References1

Roglic, Gojka. WHO Global report on diabetes: A summary. International Journal of Noncommunicable Diseases 1(1): p 3–8, Apr–Jun 2016. | DOI: 10.4103/2468-8827.184853.

Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. – 11-й выпуск. – М.; 2023. doi: https://doi.org/10.14341/DM13042.

International Diabetes Federation. IDF Diabetes Atlas. Ninth edition. 2019. URL: https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf (дата обращения – 15.01.2020).

Bhat A, Sebastiani G, Bhat M. Systematic review: preventive and therapeutic applications of metformin in liver disease. World J Hepatol. (2015) 7:1652–9. 10.4254/wjh.v7.i12.1652.

Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 2015; 100:2231–2238.

Hydes TJ, Summers N, Brown E, Alam U, Thomaides-Brears H, Wilding JPH, Cuthbertson DJ. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. Diabet Med. 2020 Nov;37(11):1793–1806. doi: 10.1111/dme.14356. Epub 2020 Jul 13.

Stynen B, Abd-Rabbo D, Kowarzyk J, Miller-Fleming L, Aulakh SK, Garneau P, et al. Changes of cell biochemical states are revealed in protein homomeric complex dynamics. Cell. (2018) 175:1418–29. 10.1016/j.cell.2018.09.050.

Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules. 2022 Jun 13;12(6):824. doi: 10.3390/biom12060824.

Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998 Apr;114(4):842–5. doi: 10.1016/s0016-5085(98)70599-2.

Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol. 2015 Jun;5(2):147–58. doi: 10.1016/j.jceh.2015.02.002. Epub 2015 Feb 16.

Tanase D.M., Gosav E. M., Costea C. F., Ciocoiu M., Lacatusu C. M., Maranduca M. A., Ouatu A., Floria M. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD) J. Diabetes Res. 2020;2020:3920196. doi: 10.1155/2020/3920196.

Lana A, Valdés-Bécares A, Buño A, et al. Serum leptin concentration is associated with incident frailty in older adults. Aging and Disease. 2017;8(2):240. doi: 10.14336/AD.2016.0819.

Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. (2015) 66:17–29. 10.1146/annurev-med-062613–093128.

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016 Aug;65(8):1038–48. doi: 10.1016/j.metabol.2015.12.012. Epub 2016 Jan 4.

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023 Apr 1;77(4):1335–1347. doi: 10.1097/HEP.0000000000000004.

Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver Int. 2020 Jun;40(6):1254–1261. doi: 10.1111/liv.14478. Epub 2020 Apr 28.

Lee CH, Lui DT, Lam KS. Non-alcoholic fatty liver disease and type 2 diabetes: An update. J Diabetes Investig. 2022 Jun;13(6):930–940. doi: 10.1111/jdi.13756.

Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022 Mar 14;22(1):63. doi: 10.1186/s12902-022-00980-1.

Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023 Aug 7;119(9):1787–1798. doi: 10.1093/cvr/cvad095.

Lana A, Valdés-Bécares A, Buño A, et al. Serum leptin concentration is associated with incident frailty in older adults. Aging and Disease. 2017;8(2):240. doi: 10.14336/AD.2016.0819.

Guo X, Yin X, Liu Z, Wang J. Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. Int J Mol Sci. 2022 Dec 7;23(24):15489. doi: 10.3390/ijms232415489.

Lumba R., Securiton V., Lee V., Long T., Klitgord N., Bhatt A., Delai P. S., Cassi K., Betancourt R., Highlander S. K., etc. A metagenomic signature based on the gut microbiome for noninvasive detection of advanced fibrosis in non-alcoholic fatty liver disease in humans. Metabo of cells. 2017;25:1054–1062.e1055. doi: 10.1016/j.cmet.2017.04.001.

Pryor R, Martinez-Martinez D, Quintaneiro L, Cabreiro F. The Role of the Microbiome in Drug Response. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:417–435. doi: 10.1146/annurev-pharmtox-010919-023612. Epub 2019 Aug 6.

de Faria Ghetti F, et al. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57(3):861–876.

Wijarnpreecha, Karn А.et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis European Journal of Gastroenterology & Hepatology: May 2020 – Volume 32 – Issue 5 – p 601–608 doi: 10.1097/MEG.0000000000001541.

Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells. 2020 Apr 3;9(4):875. doi: 10.3390/cells9040875.

Seliverstov PV, et al. Saccharomyces boulardii modulates the composition of the gut microbiota in patients with non-alcoholic fatty liver disease, thus preventing the progression of the disease. Eksp Klin Gastroenterol. 2018;(2):4–18.

Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, Bailey J, Myers RP, Rioux KP. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013;11:868–875. e1–3.

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023 Jun 24;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub ahead of print.

Van Steen M. F., de Graaf A. A., Green A. K. The effect of metformin and statins on lipid and glucose metabolism and the possible benefits of combination therapy. Cardiovask. Diabetol.2018; 17:94. doi: 10.1186/s12933-018-0738-4.

Al-Agrudi N.N., Kurzbach A., Rodionov R. N., O’Sullivan J., Roden M., Birkenfeld A. L., Pasta D. H. Is lifestyle therapy effective for the treatment of NAFLD? Trends Endocrinologist. Metab.2019; 30:701–709. doi: 10.1016/j.tem.2019.07.013.

Marshall SM. 60 years of metformin use: a glance at the past and a look to the future. Diabetologia. 2017 Sep;60(9):1561–1565. doi: 10.1007/s00125-017- 4343-y. PMID: 28776085de Faria Ghetti F, et al. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57(3):861–876.

Karlsson C. L., Onnerfält J., Xu J., Molin G., Ahrné S, Thorngren-Jerneck K. The microbiota of the gut in preschool children with normal and excessive body weight // Obesity (Silver Spring). 2012; 20: 2257–2261.

Everard A., Belzer C., Geurts L., Ouwerkerk J. P., Druart C., Bindels L. B., Guiot Y., Derrien M., Muccioli G. G., Delzenne N. M. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity // Proc Natl Acad Sci USA. 2013; 110: 9066–9071.

Shin N. R., Lee J. C., Lee H. Y., Kim M. S., Whon T. W., Lee M. S., Bae J. W. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice // Gut. 2014; 63: 727–735.

Hu H, Wang J, Li X, Shen L, Shi D, Meng J. The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis. Curr Pharm Des. 2021;27(29):3235– 3243. doi: 10.2174/1381612827666210315144821.

Donadon V, Balbi M, Mas MD, Casarin P, Zanette G (2010) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30: 750–758.

Huang Y, Wang X, Yan C, Li C, Zhang L, Zhang L, Liang E, Liu T, Mao J. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. Medicine (Baltimore). 2022 Oct 28;101(43): e31437. doi: 10.1097/MD.0000000000031437. PMID: 36316840; PMCID: PMC9622616.

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388–402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7.

Ивашкин В.Т., Маевская М. В., Жаркова М. С., Котовская Ю. В., Ткачева О. Н., Трошина Е. А. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104–140. https://doi.org/10.22416/1382–4376–2022–32–4–104–140.

The authors declare that there are no conflicts of interest present.